INTRODUCTION
Gain-of-function mutations of KRAS, NRAS, BRAF, PIK3CA genes, or loss of tumor suppressor function of PTEN, resulting in continuous activation of RAS-mitogenactivated protein kinase (MAPK) or phosphoinositide 3-kinase (PI3K) pathways, characterize most colorectal cancers (CRC) [1] . More, 12-15% CRC show high mutational load and microsatellite instability [2] . Specific mutations of the different genes involved in MAPK/PI3K pathway may confer different biological aggressiveness and effectiveness of treatment strategies.
Overall, KRAS exons 2-4 (KRAS 2-4 ), NRAS exons 2-4 (NRAS [2] [3] [4] , BRAF exon 15 (BRAF 15 ) mutant (mut) MCRC patients are prevalent [3] [4] [5] [6] . KRAS 2 mut characterize 45-55% MCRC, mostly consisting of codon 12 (80%) c.35 G>A (G12D) and c.35 G>T (G12V) transversions [7, 8] , and codon 13, prevalently c.38 G>A (G13D) mut, and impair the intrinsic GTPase activity of RAS, leading to constitutive, growth-factor-receptor independent activation of downstream signaling [9] [10] [11] . In MCRC patients, the reported prevalence of KRAS [2] [3] [4] mut is 52.8%, NRAS 2-4 mut 5.3%, BRAF 15 mut 4.7-8.7%, prevalently c.1799 T>A (V600E) [3, 12] . Massive parallel sequencing of multiple genes by different NGS platforms enables mutation detection highly accurate and it is able to detect mutations at 5% allelic fraction (AF) [13, 14] . PGM/ Colon Lung Cancer Panel identified all point mutations, and failed in 4.4% CRC mutant samples. In early CRC, KRAS [2] [3] [4] 37.8%, and NRAS 2-4 4.6% mut were reported [13, 14] . KRAS, NRAS mut were mutually exclusive, BRAF mut (mostly not V600E) occasionally, PIK3CA mut frequently coexisted with RAS mut. Detection of multiple gene mutations and dynamic molecular characterization in the individual patient, could help monitoring biological evolution of metastatic disease, with prognostic and predictive clinical implications.
Treatment strategy of MCRC patients differs according to patient's fitness (age, comorbidity), metastatic extension (liver-limited (L-L) or other/multiple metastatic sites (O/MM)), and KRAS 2-4 /NRAS 2-4 /BRAF 15 genotype [9, 6, 15] . KRAS 2-4 /NRAS 2-4 wt or mut genotype addresses the addiction of anti-Vascular Endothelial Growth Factor (VEGF) or anti-Epidermal Growth Factor Receptor (EGFR) to first line triplet or doublet chemotherapy of MCRC [3, [16] [17] [18] : anti-EGFR drugs in RAS wt [16] [17] [18] ; anti-VEGF drugs in RAS wt and mut patients [3] . KRAS wt genotype predicted favourable clinical outcomes of anti-EGFR or anti-VEGF molecules added to doublet chemotherapy [19] .
Clinical outcome of MCRC patients treated with BEV-containing chemotherapy is not significantly affected by KRAS 2 status, wt or mut; median OS ranges between 29.9-38 months, and 19.9-21 months, respectively [19, 20, 9] . In KRAS 2 mut patients, retrospective analysis showed that BEV addition to irinotecan, 5-fluorouracil, leucovorin (IFL) was predictive of significantly prolonged PFS, compared to IFL [19, 20] ; in KRAS 2 wt and mut MCRC patients treated with BEV added to IFL, median OS was 27.7 and 19.9 months, respectively, not significantly different [19, 20] . The prognostic relevance of KRAS 2 and BRAF 15 genotype was not significantly different, even though the hazard ratio (HR) was 0.64 and 0.38, respectively. A significantly better prognosis was reported only when KRAS 2 /BRAF 15 wt patients were compared with patients harboring mutations in KRAS 2 or BRAF 15 genes (HR 0.51) [19] . Intensive first line treatment adding BEV to triplet chemotherapy, according to FOLFOXIRI plus BEV and FIr-B/FOx, consisting of 5-fluorouracil associated to alternating irinotecan/BEV or oxaliplatin, according to previously reported weekly schedule [5] , increased activity and efficacy of MCRC patients: objective response rate (ORR) 77-82%, PFS 13.1 and 12 months, OS 30.9 and 28 months, not significantly different in KRAS 2 wt and mut patients [5, 3] . Median OS of patients treated with FIr-B/ FOx in KRAS 2 wt and mut patients was 38 months and 21 months, respectively, not significantly different [9] ; the prevalent KRAS 2 c.35 G>A (G12D) mutant genotype may significantly affect worse OS [10, 11] . More recently, KRAS 2 genotype was reported as affecting significantly different PFS and OS in patients treated with XelOx/BEV [21] . Retrospective analysis of clinical outcome according to KRAS 2-4 /NRAS 2-4 /BRAF 15 genotype in PRIME, FIRE-3, PEAK, TRIBE randomized trials showed that EGFRand VEGF-inhibitors are more and equivalently effective in KRAS 2-4 /NRAS 2-4 wt patients [16] [17] [18] 3] . In the TRIBE study, FOLFOXIRI-Bev may predict a favourable effect in BRAF 15 mut patients, compared to FOLFIRI-BEV [3] .
The present study evaluated the prevalence, individual distribution and prognostic relevance of KRAS [2] [3] [4] 15 wt patients were 62 (92.5%), mut 5 (7.5%). KRAS exon 2 mutational status was discordant between previous monogenic evaluation and NGS data in 10 patients (15.9%): 5 (7.9%) evaluated as mut by monogenic assay were wt by NGS; 4 (6.3%) wt by monogenic assay showed a KRAS exon 2 mutation by NGS; a different KRAS exon 2 mutation was reported in 1 patient (1.6%). Table 3 shows the prevalence of mutant samples, with single and multiple mutations, according to the mutation detection criteria. Overall, 60 mutations were detected in 49 mut samples, range 1-3 mut (median 1.22 mut/mut sample) at >500×cov and >1% AF detection criteria: 43 (71.7%) at >1000×cov/>5% AF; 9 (15%) at >500×cov/>5% AF; 8 (13.3%) at >1000×cov/<5% AF. The distribution of mut samples according to the mutation detection criteria, >1000×cov and >5% AF, >500×cov and >5%, and >1000×cov and <5% AF was, respectively: in 49 KRAS 2- 15 mut, all ≥2 mut (7.5%). Table 4 shows the panel of detected mutations, and of the >2 mut samples according to mutation detection criteria. Distribution of KRAS 2 mut was: codon 12, 35 (55.6%); codon 13, 5 (7.9%). KRAS 2 c.35 G>A (G12D) was detected in 16 (25.4%) samples, 13 (20.6%) single and 3 (4.8%) ≥2 mut: 1 associated with NRAS 2 c.34 G>A (G12S) and BRAF 15 c.1756 G>A (E586K) mutations; 1 associated with NRAS 2 c.38 G>T (G13V) and BRAF 15 c.1405 G>A (G469R) mutations; 1 associated with NRAS 2 c.182 A>G (Q61R) mutation. KRAS 2 c.35 G>T (G12V) was detected in 15 (23.8%) samples, 13 (20.6%) single and 2 (3.2%) ≥2 mut: 1 associated with a KRAS 4 c.436 G>A (A146T) mutation; 1 associated with a BRAF 15 c.1756 G>A (E586K) mutation. Other KRAS 2 mutations were: c.35 G>C (G12A) 1 (1.6%); c.34 G>C (G12R) 1 (1.6%); c.34 G>A (G12S) 2 (3.2%), including 1 associated with KRAS c.37 G>A (G13S) and NRAS c.35 G>A (G12D); c.38 G>A (G13D), 5 (7.9%), 4 (6.4%) single and 1 (1.6%) ≥2 mut, associated with a BRAF 15 c.1406 G>C (G469A) mutation. KRAS 3 codon 61 mut were detected in 2 patients (3.2%), specifically c.182 A>T (Q61L) and c.182 A>G (Q61R), 1 patient each (1.6%). Distribution of NRAS mutations was: NRAS codon 12, 2 (3.0%), specifically c.34 G>A (G12S) associated to KRAS c.35 G>A and BRAF c.1756 G>A mutations, and c.35 G>A (G12D) associated to double KRAS mutations; NRAS codon 13, 4 (6%), c.37 (Table 5) [9, 10, 22] : PFS 13 months (3-113+ months), OS 27 months (4-119+ months); in KRAS 2 wt and mut, median PFS was 14 (3-93+ months) and 12 months (3-113+ months), median OS 28 (6+−97 months) and 21 months (4-119+ months), respectively, not significantly different [23] ( Figure 1A, 1B) ; in c.35 G>A KRAS mut, median PFS was 8 months (3-113+ months), median OS 14 months (4-119+ months), not significantly different compared with wt ( Figure 1C, 1D ). Among KRAS 2-4 wt and mut, median PFS was 13 (3-93+ months) and 12 months (3-113+ months), median OS 27 months equivalently (6+−97 and 4-119+ months), respectively, not significantly different (Figure 2A ). Among NRAS [2] [3] [4] wt and mut, median PFS was 16 (3-113+ months) and 12 months (6-93+ months), median OS 28 (4-119+ months) and 22 months (8-93+ months), respectively, not significantly different ( Figure 2B ). Among BRAF 15 wt and mut, median PFS was 14 (3-113+ months) and 8 months (6-17 months), median OS was 28 (4-119+ months) and 11 months (8-94+ months), respectively ( Figure 3A) , not significantly different. Among KRAS 2-4 /NRAS 2-4 /BRAF 15 wt and mut, median PFS was 18 (3-33 months) and 12 months (3-113+ months), median OS was 28 (6+−97 months) and 22 months (4-119+ months), respectively ( Figure 3B ). PFS and OS of wt compared to mut patients was not significantly different (P = 0.866 and 0.956, respectively). Among mutant patients with ≥2 compared to 1 mut gene, PFS was 11 and 14 months, OS was 22 15 mut at >1000×cov and >5% AF were 47.6% and 63.5%, respectively, consistent with that previously reported in the same MCRC cohort by our group using direct sequencing [9, 10] , and in the range of reported 45-55% KRAS 2 and 65.6% KRAS 2-4 /NRAS 2-4 /BRAF 15 mut [3] . In the retrospective evaluation of TRIBE trial [3] , KRAS [2] [3] [4] , NRAS [2] [3] [4] , BRAF 15 mutations were detected in www.oncotarget.com 52.8%, 5.3% and 7.5% of patients, respectively; all wildtype were 34.4%. The application of >500×cov and >1% AF mutation criteria may increase detectable mutations due to the increased NGS diagnostic accuracy, that may detect tumoral clonal heterogeneity: KRAS 2-4 mut were prevalently detected at >1000×cov/>5% AF (50.8%), while NRAS 2-4 mut (16.4%) were frequently detected at 500-1000xcov and <5%AF (6%), and BRAF 15 mut (7.5%) were all detected at 500-1000×cov and <5%AF. Thus, KRAS 2-4 /NRAS 2-4 / BRAF 15 mutations were frequently detected (28.3%) at 500-1000×cov and <5%AF.
Present findings show that RAS mutations were enriched in MCRC patients, compared to early CRC where KRAS 2-4 37.8%, and NRAS 2-4 4.6% mut were reported by the same NGS platform [13, 14] . KRAS 2-4 /NRAS 2-4 /BRAF 15 mut were often detected at <5% AF (13.3%), all involving MCRC patients harbouring >2 KRAS and/or NRAS mut and prevalently involving atypical BRAF mutations, different from that typically reported (codon 600) in CRC [14] . All BRAF 15 15 mut, as recently reported [13, 14] . One MCRC patient was only detected at 500-1000×cov and <5%AF (1.6%), and harbored NRAS c.182 A>G (Q61R) associated to BRAF c.1796 C>T (T599I) mutations. Thus, massive parallel sequencing by Ion torrent platform can increase mutation detection by increasing diagnostic accuracy, if >1% mutant AF with >1000×cov is included to specifically detect clonal heterogeneity involving KRAS, NRAS and atypical BRAF mutations, thus increasing the detection of multiple genes mutations in individual MCRC patients. To this aim, NGS is able to detect mutant alleles at the 5% level [13, 14] .
Specific mutations of different genes involved in the same signalling pathway (BRAF and RAS mutations) can confer different biological aggressiveness and effectiveness of treatment strategies. Preliminary analysis of differential clinical outcome in overall MCRC patients treated with FIr-B/FOx intensive first line treatment according to KRAS 2 genotype confirmed previously reported median PFS 13 months and OS 27 months, a trendy worse OS 21 months in KRAS 2 mut, and PFS 8 months and OS 14 months in the prevalent KRAS 2 c.35G > A mut MCRC patients [11] . Clinical outcome was not significantly different in KRAS [2] [3] [4] , NRAS [2] [3] [4] , BRAF 15 mut and wt MCRC patients. The 5 BRAF 15 mut, all atypical and associated to other KRAS [2] [3] [4] and/or NRAS 2-4 mut, compared to wt MCRC patients showed trendy worse, not significantly different, PFS 8 months and OS 11 months, even if treated with BEV added to triplet chemotherapy. Worse prognosis was previously shown by the prevalent BRAF 15 c.1799 T > A (V600E) mutation, characterizing 4.7-8.7% CRC, in MCRC patients treated with doublet chemotherapy alone or added to cetuximab, BEV, and cetuximab plus BEV, with median PFS 5.6-8 months and median OS 10.3-15.9 months [24] [25] [26] . The favourable predictive effect of cetuximab or BEV addiction to chemotherapy in KRAS exon 2 wild-type patients was not significantly confirmed in BRAF mutant MCRC patients [20, 24, 25] . Mutations in BRAF gene occur in two regions of the BRAF kinase domain, exon 15, the activation segment (which protects the substrate binding site), and, less commonly, exon 11, the G loop (which mediates ATP-binding). Less common BRAF mutations at codons 594 and 596 correlated with longer OS when compared with BRAF V600E mutations (62 vs 12.6 months, P = 0.002) [27] , and trendy longer compared to BRAF wild-type (35.9 months) in MCRC patients treated with FOLFOXIRI/BEV [3] . 
MATERIALS AND METHODS

Patients and samples
Eighty-seven consecutive, unselected, MCRC patients were enrolled in previously reported phase II study and the expanded clinical program proposing FIr-B/FOx as first line treatment [5, 9] . KRAS [2] [3] [4] analyses recommendations for clinical implications [28] , by SNaPshot ® multiplex, and/or direct sequencing, as previously reported [9] . [13, 14] . Molecular diagnostic criteria for mutation detection were: >500×sequence coverage; >1% mutant allelic fraction.
Mutation detection by massive parallel sequencing
Study design
A retrospective analysis has been planned to evaluate prognostic relevance of KRAS 2-4 /NRAS 2-4 /BRAF 15 genotype on clinical outcome of MCRC patients treated with first line FIr-B/FOx regimen. Clinical criteria of efficacy were PFS, OS, evaluated using Kaplan and Meier method [22] . Patients were evaluated according to involved metastatic sites, classified as L-L and O/MM. Log-rank test was used to compare PFS and OS in different subgroups [23] . PFS was defined as length of time between beginning of treatment and disease progression or death (resulting from any cause) or to last contact; OS as length of time between beginning of treatment and death or to last contact. 
CONCLUSIONS
